There are 360 resources available
104P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: a phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
105P - Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): single arm phase II study
Presenter: Peng Jin
Session: Poster Display
106P - Zanubrutinib in combination with tislelizumab in patients with refractory diffuse large B-cell lymphoma (DLBCL): a phase II study
Presenter: lijie zuo
Session: Poster Display
108P - Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Presenter: MARA PERSANO
Session: Poster Display
109P - Impact of anti-drug antibody (ADA) on naxitamab efficacy and safety
Presenter: Brian Kushner
Session: Poster Display
111P - Identification of Atezolizumab plus BEvacizumab prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma: the ABE index.
Presenter: MARA PERSANO
Session: Poster Display
112P - Pseudoprogression predicts better prognosis in advanced non small cell lung cancer treated with immune-check point inhibitors
Presenter: Nihan Senturk Oztas
Session: Poster Display
113P - The prognostic and predictive roles of serum C-reactive protein and PD-L1 in non-small cell lung cancer
Presenter: Saara Kuusisalo
Session: Poster Display